Compare VWAV & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VWAV | BYSI |
|---|---|---|
| Founded | 2024 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.4M | 35.8M |
| IPO Year | 2025 | 2016 |
| Metric | VWAV | BYSI |
|---|---|---|
| Price | $0.89 | $0.67 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.3M | 1.9M |
| Earning Date | 05-18-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.83 | $0.57 |
| 52 Week High | $15.80 | $2.44 |
| Indicator | VWAV | BYSI |
|---|---|---|
| Relative Strength Index (RSI) | 29.88 | 27.94 |
| Support Level | N/A | N/A |
| Resistance Level | $2.14 | $1.30 |
| Average True Range (ATR) | 0.22 | 0.10 |
| MACD | 0.07 | 0.01 |
| Stochastic Oscillator | 6.04 | 8.90 |
VisionWave Holdings Inc is a technology company focused on the development and commercialization of artificial intelligence (AI) and autonomous solutions across air, ground and sea environments. Through its subsidiary, the Company designs and deploys technologies including radars, radio frequency (RF) sensing, unmanned aerial and ground systems, remote weapon stations and active protection systems for defense, military, homeland security and industrial applications. Its proprietary AI engine supports autonomous decision-making and product lines at various stages of development and commercialization. Revenue is generated through product sales, technology licensing, strategic alliances and joint ventures, with products including C-UAS, multi-purpose autonomous UAS and Vision-AI technology.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.